This page ranks cell types relevant to neurodegenerative diseases by various criteria including disease relevance, research activity, therapeutic potential, and knowledge base coverage in NeuroWiki.
| Rank | Cell Type | Role in AD | Research Activity |
|---|---|---|---|
| 1 | Microglia | Aβ clearance, neuroinflammation | Very High |
| 2 | Neurons (cortical) | Synaptic loss, tau pathology | Very High |
| 3 | Astrocytes | Aβ clearance, metabolic support | High |
| 4 | Oligodendrocytes | Myelin maintenance | Moderate-High |
| 5 | Pericytes | Blood-brain barrier integrity | High |
| 6 | Endothelial cells | BBB function | Moderate |
| 7 | Choroid plexus | CSF production, clearance | Moderate |
| 8 | Neural stem cells | Regeneration potential | Moderate |
| 9 | T cells (brain) | Neuroinflammation | Low-Moderate |
| 10 | Mast cells | Neuroinflammation | Low |
| Rank | Cell Type | Role in PD | Research Activity |
|---|---|---|---|
| 1 | Dopaminergic neurons | Motor symptoms, Lewy bodies | Very High |
| 2 | Microglia | Neuroinflammation, α-syn clearance | Very High |
| 3 | Astrocytes | Metabolic support, protein clearance | High |
| 4 | Serotonergic neurons | Non-motor symptoms | Moderate-High |
| 5 | Noradrenergic neurons | Non-motor symptoms | Moderate |
| 6 | Enteric neurons | GI involvement, alpha-syn spread | High |
| 7 | Oligodendrocytes | Myelin integrity | Moderate |
| 8 | Schwann cells | Peripheral nerve function | Low-Moderate |
| 9 | Neural stem cells | Regeneration potential | Moderate |
| 10 | T cells | Neuroinflammation | Low-Moderate |
| Rank | Cell Type | Role in ALS | Research Activity |
|---|---|---|---|
| 1 | Motor neurons | Progressive loss | Very High |
| 2 | Astrocytes | Non-cell autonomous toxicity | Very High |
| 3 | Microglia | Neuroinflammation | Very High |
| 4 | Oligodendrocytes | Myelin degeneration | High |
| 5 | Schwann cells | Peripheral nerve | Moderate-High |
| 6 | Interneurons | Network dysfunction | Moderate |
| 7 | Muscle cells | Denervation | Moderate |
| 8 | Endothelial cells | BBB integrity | Moderate |
| 9 | Neural stem cells | Regeneration | Low-Moderate |
| 10 | T cells | Inflammation | Low |
Cell types and cell-based therapies with highest potential:
| Rank | Cell Type | Therapy Type | Development Stage |
|---|---|---|---|
| 1 | Dopaminergic neurons | Cell replacement | Phase 1-2 |
| 2 | Neural stem cells | Cell therapy | Phase 1-2 |
| 3 | Microglia (modified) | Gene therapy | Preclinical |
| 4 | Astrocytes (protective) | Cell therapy | Preclinical |
| 5 | Oligodendrocyte progenitors | Remyelination | Preclinical |
| 6 | Motor neurons (iPSC) | Disease modeling | Research |
| 7 | Cholinergic neurons | Cell replacement | Preclinical |
| 8 | Serotonergic neurons | Cell replacement | Preclinical |
Microglia and astrocytes become activated in neurodegenerative diseases, releasing pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that contribute to neuronal death[1]. The TREM2 receptor on microglia is critical for Aβ clearance and has become a major therapeutic target.
Neurons accumulate aggregated proteins (Aβ, tau, α-syn, TDP-43) that form toxic inclusions. Cellular clearance mechanisms (autophagy, ubiquitin-proteasome) become impaired[2].
Microglia in Alzheimer's disease. Nat Rev Neurosci. 2019. ↩︎
Cellular mechanisms of protein aggregation. Nat Rev Mol Cell Biol. 2010. ↩︎